Get the latest news, insights, and market updates on VTYX (Ventyx Biosciences, Inc.). Explore the news page 5 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors
VTX3232 demonstrated significant reductions in cardiovascular risk factors, with additional benefits when combined with semaglutide VTX3232 monotherapy achieved ~80% reduction in hsCRP within the first weekVTX3232 monotherapy reduced IL-6 levels at Week 12 below the threshold for cardiovascular risk of ≤1.65ng/L1Statistically significant reductions in Lp(a) and liver inflammationNo effect on weight either as a monotherapy or as add-on to semaglutide VTX3232 was safe and well tolerated both as a Oct 22, 2025 - $VTYX
3 Penny Stocks With Market Caps Over $100M And Promising Growth
As U.S. stock indexes reach new all-time highs, driven by significant partnerships and strategic investments in the tech sector, investors are exploring diverse opportunities across the market spectrum. The term 'penny stocks' might feel like a relic of past market eras, but the potential they represent is as real as ever. Typically referring to smaller or relatively new companies, these stocks can provide a mix of affordability and growth potential when paired with strong financials. Sep 23, 2025 - $VTYX
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that Company executives will participate in the following upcoming investor conferences: 2025 Wells Fargo Healthcare ConferenceLocation: Boston, MADate: Friday, September 5, 2025Time: 11:00-11:35 AM EDT Morgan Aug 27, 2025 - $VTYX
Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress
Positive topline Phase 2a biomarker data position VTX3232 as a potential disease-modifying therapy for patients with Parkinson’s disease Data from the Phase 2 study of VTX2735 in patients with recurrent pericarditis expected in Q4 2025 Phase 2 study of VTX3232 in participants with obesity and cardiometabolic risk factors is fully-enrolled and on track to yield topline data in early Q4 2025 Cash, cash equivalents and marketable securities balance of $209.0M as of June 30, 2025 expected to fund pl Aug 7, 2025 - $VTYX
Top Penny Stocks To Watch In July 2025
Over the last 7 days, the United States market has risen 1.4%, contributing to a 17% climb over the past year, with future earnings expected to grow by 15% annually. Penny stocks may be a throwback term, but they represent opportunities that are still very much relevant today. By focusing on those with strong balance sheets and solid fundamentals, investors can potentially find hidden gems in this investment area amidst current market conditions. Jul 28, 2025 - $VTYX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple